For many wheelchair users, the chance to stand and walk has been limited to rehabilitation clinics, under the watch of therapists and with crutches or a walker for balance. That changed in August 2026, when the United States Food and Drug Administration cleared Eve, a personal self-balancing exoskeleton built by the French company Wandercraft, for eligible adults living with spinal cord injuries. Eve is described as the first self-balancing personal exoskeleton cleared for use outside a clinic. It uses motors and sensors to keep the wearer upright automatically, so eligible users who can operate its remote control can stand, walk, bend and turn hands-free, and use their hands for everyday tasks. The device was commercially launched in the United States on September 17, 2026. It builds on Wandercraft’s earlier rehabilitation exoskeleton, Atalante X, which is used in more than 150 rehabilitation and research centres around the world. Users steer it with a small handheld controller, and the device adjusts its balance with every step.
What the Evidence Shows
The clearance comes with clear limits, and the company is careful to state them. Eve is designed for use on level indoor surfaces and level outdoor areas immediately next to a building, such as patios and terraces, and always under the supervision of a specially trained companion. It is meant to complement a wheelchair, not replace it, and every user needs a prescription, a clinical assessment, fitting and training before taking one home. Eligibility is not restricted by the level of spinal cord injury, but depends on the person being able to operate the handheld controller safely and having no medical reason not to use it. The clearance was supported by a three-site clinical trial in New York and New Jersey, in which participants reported improvements in health, wellbeing, endurance and sitting balance. Wandercraft expects Eve could become eligible for Medicare reimbursement within 60 to 90 days of clearance, which would put it within reach of more people. Reporting and analysis from sources such as MIT Technology Review track the same developments, and specialists following self-balancing exoskeleton Eve say the direction is now consistent across independent lines of evidence.
The Wider Context
The wider context is an industry learning to ship capability and restraint together. Products built around self-balancing exoskeleton Eve now launch with safety evaluations, usage data and rollback plans as standard, because enterprise buyers and regulators ask for them in the first meeting. Companies that treated those questions as friction are discovering they have become the purchase criteria.
What Happens Next
What happens next for self-balancing exoskeleton Eve depends less on another breakthrough than on the unglamorous work of reliability, pricing and support. The buyers evaluating it now are not enthusiasts; they are operators with budgets and auditors, and their checklists will decide the timeline. On the evidence of the current pilots, the technology has earned the right to be judged by them. You can follow related developments in our coverage of technology.
There is a practical lesson in all of this for readers deciding what to do today. Start with the verified facts, be wary of anyone promising certainty, and prefer reversible steps while the evidence is still developing. Circumstances differ by country, income and personal situation, so general guidance should always be weighed against your own context before you act on it in any significant or lasting way.